Data MATRIX and Webiomed became partners in routine clinical research

RWE-research has been in use for decades, but recent advances in digital analytics and artificial intelligence are allowing them to be used in new ways.

RWEs go beyond the results of clinical trials with a relatively small number of patients to provide a complete picture of how a drug will behave in real-world settings on data of hundreds of thousands of people.

In essence, RWE is the very mechanism that will allow healthcare to become patient-centered in the truest sense of the word: providing the right treatment to the right patient at the right time.

This year, thanks to the regulatory sandbox, Data MATRIX became the only Russian company working in Real World Evidence that has the right to officially conduct RWE studies on Russian data.  This is mostly impersonal electronic medical records (EMC) data provided by medical institutions throughout Russia.

Data MATRIX has been working with clinical data since 2009.  In 2019, Data MATRIX focused entirely on RWE research. And in less than two years it conducted 10 studies for pharma companies included in the top ten of Big Pharma

Webiomed's platform analyzes anonymized EMC data, identifies risk factors and provides actionable recommendations to physicians and patients, and management analytics to healthcare executives. Webiomed is used to predict the potential development of diseases and their complications at both the personal and population levels. The system is able to analyze unstructured medical data and has its own biomedical databank with more than 120 million medical records and more than 3 million digital twins of patients.

By combining the efforts of the two technology companies, in-depth analysis of therapy efficacy based on clinical outcome data from real-world patient management practices is expected to improve access to safe and effective treatment for the public and determine the efficacy and safety of any new drug.

"In the burgeoning RWE-research industry, first, access to data, and second, the collaboration of technology companies working in the medical field to conduct more complete and higher quality studies is important. - According to Ekaterina Krinitsyna, Head of Business Development - Our company has built up its proprietary partner network and we are happy that K-Sky has become our partner in the development and promotion of RWE-research in Russia.

 

"Currently, the relevance and growing importance of RWE research in modern medicine is obvious. To perform such research qualitatively, we need the right technology to extract relevant medical information from electronic medical records. We are glad to cooperate with Data MATRIX, which will enable us to conduct joint research based on real clinical practice data and thereby help to solve urgent tasks of practical healthcare and development of pharmaceutical companies," said K-Sky Development Director Alexander Gusev.

 

 

 

18 October 2021

Other news